Similar articles

• Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

  Hochhaus A. Hochhaus A. Ann Hematol. 2004;83 Suppl 1:S65-6. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124676 Review. No abstract available.
• STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.

  Kumar L, Kumari M, Menon H. Kumar L, et al. Natl Med J India. 2002 Sep-Oct;15(5):298. Natl Med J India. 2002. PMID: 12502149 No abstract available.
• Imatinib mesylate--a new oral targeted therapy.

  Savage DG, Antman KH. Savage DG, et al. N Engl J Med. 2002 Feb 28;346(9):683-93. doi: 10.1056/NEJMra013339. N Engl J Med. 2002. PMID: 11870247 Review. No abstract available.
• Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

  Goldman J. Goldman J. Nat Clin Pract Oncol. 2005 Mar;2(3):126-7. doi: 10.1038/ncponc0110. Nat Clin Pract Oncol. 2005. PMID: 16264901 No abstract available.
• FDA approves Gleevec for pediatric leukemia.

  [No authors listed] [No authors listed] FDA Consum. 2003 Jul-Aug;37(4):6. FDA Consum. 2003. PMID: 12971334 No abstract available.